1. Home
  2. CABR vs BIVI Comparison

CABR vs BIVI Comparison

Compare CABR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CABR

Caring Brands Inc.

N/A

Current Price

$1.33

Market Cap

12.1M

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.75

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABR
BIVI
Founded
2020
2013
Country
United States
United States
Employees
3
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
11.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CABR
BIVI
Price
$1.33
$1.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
82.4K
100.2K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.88
52 Week High
$1.65
$9.09

Technical Indicators

Market Signals
Indicator
CABR
BIVI
Relative Strength Index (RSI) 57.25 60.44
Support Level $0.80 $1.17
Resistance Level $1.35 $1.78
Average True Range (ATR) 0.13 0.15
MACD 0.01 0.02
Stochastic Oscillator 54.55 76.47

Price Performance

Historical Comparison
CABR
BIVI

About CABR Caring Brands Inc.

Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: